Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits

Volume
60
Pagination
1042A - 1042A
ISSN
0270-9139
Metadata
Show full item record
Authors
Martin, NK; Vickerman, P; Dore, GJ; Grebely, J; Foster, GR; Miners, A; Hutchinson, S; Goldberg, DJ; Martin, TC
URI
http://qmro.qmul.ac.uk/jspui/handle/123456789/7003
Collections